Medication classes
Aminosalicylate articles covering 5-ASA medicines such as mesalamine and sulfasalazine in IBD care. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
29 articles
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
The study links TXNIP/NLRP3 inflammatory signaling to disease features in an animal UC model and tests engeletin and rosuvastatin as interventions that lowered inflammatory markers—information relevant to researchers...
Adding a mesalazine retention enema to oral mesalazine improved short-term symptom relief and endoscopic signs of mucosal healing in mild-to-moderate left-sided ulcerative colitis in this retrospective study. That could...
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
Coexistence of ulcerative colitis and collagenous colitis is rare but can change diagnosis and management. Stool calprotectin and biopsies helped identify and monitor disease activity, and adjusting mesalazine coincided...
This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
Targeted release of mesalamine to the colon could increase local drug levels and reduce upper-GI exposure and systemic side effects. New delivery platforms may improve effectiveness for ulcerative colitis without...
Patients with ulcerative colitis who cannot tolerate 5-ASA need alternative maintenance options. This study suggests azathioprine showed comparable continuation, safety, and endoscopic outcomes whether or not patients...
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
If your Crohn’s gets worse, your care plan may change — from new medicines to nutritional support or surgery — and this article summarizes common steps doctors take to prevent complications and control inflammation.
